Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel

Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil

“…This may have an important in vivo bearing where conjugating the nanoparticles with ligand would ferry them to the tumor cells and sparing non-tumor cells, thus with the interception of minimal side-effects. The results are in line with those observed by Miglietta et al (2000) for solid lipid nanoparticles using doxorubicin and paclitaxel as model drugs…”

“…Cellular cytotoxicity was assessed by tetrazolium dyebased MTT assay following a previously reported procedure (Miglietta et al, 2000;Zhang et al, 2004). EAT cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotics at 37°C in a humidified incubator containing 5% CO 2 .…”

Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation

“…Elastic liposomes mainly consist of phosphatidyl choline, a natural bioacceptable surfactant that is biocompatible and biodegradable. Miglietta et al (2002) have studied the cytotoxicity of a solid lipid nanospheres carrier system consisting of phosphatidylcholine and natural surfactant and similarly reported significantly (p < 0.05) less cytotoxicity. Table 2 reports IC 50 values for paclitaxel elastic liposomal and marketed formulation on the A549 cells for 24 and 48 h. Figure 4b shows the percent cell viability after exposure to paclitaxel elastic liposomal and marketed formulation in a concentration range for 24 and 48 h. We can see from this figure that the paclitaxel elastic liposomal formulation showed advantages in achieving the lower cell viability or higher cytotoxic effects in comparison to the commercial formulation.…”

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

“…Concerning the body distribution, doxorubicinloaded SLNs caused higher drug concentrations in lung, spleen and brain, while the solution led to a distribution more into liver and kidneys [76]. Furthermore, incorporation of doxorubicin into SLNs strongly enhanced its cytotoxicity in several cell lines [77,78]. In particular, in the human colorectal cancer cell line HT-29, the intracellular doxorubicin content was double after 24 h exposure to loaded SLNs versus the conventional drug formulation [78].…”

“…Sterically stabilized SLNs were also prepared to prolong the blood circulation time following intravenous administration [107]. Incorporation of paclitaxel into SLNs enhanced paclitaxel cytotoxicity on the human breast adenocarcinoma cell line MCF-7, but not on the human promyelocytic leukemia cell line HL-60 [77].…”